>
Arcutis Biotherapeutics Inc logo

ARQT - Arcutis Biotherapeutics Inc Share Price

$25.75 0.2  0.8%

Last Trade - 14/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £913.0m
Enterprise Value £596.3m
Revenue £n/a
Position in Universe 2579th / 6851
Bullish
Bearish
Unlock ARQT Revenue
Momentum
Relative Strength (%)
1m -6.73%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 17.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ArcutisBiotherapeutics Inc revenues was not reported. Net lossincreased 29% to $36M. Higher net loss reflects Stock-basedCompensation in SGA increase from $574K to $7M (expense),General and administrative - Balancing increase from $2.9Mto $7.5M (expense), Stock-based Compensation in R&Dincrease from $416K to $1.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARQT Revenue Unlock ARQT Revenue

Net Income

ARQT Net Income Unlock ARQT Revenue

Normalised EPS

ARQT Normalised EPS Unlock ARQT Revenue

PE Ratio Range

ARQT PE Ratio Range Unlock ARQT Revenue

Dividend Yield Range

ARQT Dividend Yield Range Unlock ARQT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ARQT EPS Forecasts Unlock ARQT Revenue
Profile Summary

Arcutis Biotherapeutics Inc is a United States-based biopharmaceutical company. The Company focuses on developing treatments for unmet needs in immune-mediated dermatological diseases or immune-dermatology. Its strategy is to identify and develop treatments against validated biological targets in dermatology that deliver a differentiated clinical profile that addresses shortcomings of existing therapies in targeted indications.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: 24
No. of Employees: 54
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 50,205,046
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARQT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARQT
Upcoming Events for ARQT
Monday 9th August, 2021 Estimate
Q2 2021 Arcutis Biotherapeutics Inc Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 Arcutis Biotherapeutics Inc Earnings Release
Frequently Asked Questions for Arcutis Biotherapeutics Inc
What is the Arcutis Biotherapeutics Inc share price?

As of 14/05/21, shares in Arcutis Biotherapeutics Inc are trading at $25.75, giving the company a market capitalisation of £913.0m. This share price information is delayed by 15 minutes.

How has the Arcutis Biotherapeutics Inc share price performed this year?

Shares in Arcutis Biotherapeutics Inc are currently trading at $25.75 and the price has moved by -4.7% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arcutis Biotherapeutics Inc price has moved by -33.09% over the past year.

What are the analyst and broker recommendations for Arcutis Biotherapeutics Inc?

There are no analysts currently covering Arcutis Biotherapeutics Inc.

When will Arcutis Biotherapeutics Inc next release its financial results?

Arcutis Biotherapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Arcutis Biotherapeutics Inc dividend yield?

Arcutis Biotherapeutics Inc does not currently pay a dividend.

Does Arcutis Biotherapeutics Inc pay a dividend?

Arcutis Biotherapeutics Inc does not currently pay a dividend.

When does Arcutis Biotherapeutics Inc next pay dividends?

Arcutis Biotherapeutics Inc does not currently pay a dividend.

How do I buy Arcutis Biotherapeutics Inc shares?

To buy shares in Arcutis Biotherapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arcutis Biotherapeutics Inc?

Shares in Arcutis Biotherapeutics Inc are currently trading at $25.75, giving the company a market capitalisation of £913.0m.

Where are Arcutis Biotherapeutics Inc shares listed? Where are Arcutis Biotherapeutics Inc shares listed?

Here are the trading details for Arcutis Biotherapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ARQT
What kind of share is Arcutis Biotherapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Arcutis Biotherapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arcutis Biotherapeutics Inc share price forecast 2021?

Shares in Arcutis Biotherapeutics Inc are currently priced at $25.75. At that level they are trading at 0.119% discount to the analyst consensus target price of 0.00.

Analysts covering Arcutis Biotherapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -4.362 for the next financial year.

How can I tell whether the Arcutis Biotherapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcutis Biotherapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 7.73%. At the current price of $25.75, shares in Arcutis Biotherapeutics Inc are trading at -7.4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arcutis Biotherapeutics Inc PE Ratio?

We were not able to find PE ratio data for Arcutis Biotherapeutics Inc.

Who are the key directors of Arcutis Biotherapeutics Inc?

Arcutis Biotherapeutics Inc's management team is headed by:

Todd Watanabe - PRE
Scott Burrows - CFO
David Osborne - CFD
Heather Armstrong - VPR
Kimberly Lathroum - VPR
Halley Gilbert - DRC
Jay Ramsinghani - VOP
Howard Welgus - DRC
Patricia Turney - SVP
David Berk - VPR
Patrick Heron - CHM
Bhaskar Chaudhuri - IND
Jonathan Silverstein - IND
Bethany Dudek - VPR
Terrie Curran - DRC
Who are the major shareholders of Arcutis Biotherapeutics Inc?

Here are the top five shareholders of Arcutis Biotherapeutics Inc based on the size of their shareholding:

Frazier Healthcare Partners Venture Capital
Percentage owned: 16.8% (8.43m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 12.66% (6.35m shares)
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 12.1% (6.07m shares)
Bain Capital Life Sciences Investors, LLC Investment Advisor
Percentage owned: 7.93% (3.98m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.1% (2.06m shares)
Similar to ARQT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.